Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of TBE025 in Healthy Adults
NCT07377253Phase 1Not yet recruiting
- Sponsor
- Giuseppe Pantaleo
- Start
- Jan 2026
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of TBE025 in tick-borne encephalitis (TBE) (3 cohorts), sponsored by Giuseppe Pantaleo. Primary endpoints: Maximum Tolerated Dose at 84 days, Adverse Events at 84 days and 1 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
TBE025
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on NCT07377253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07377253.